French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

The trade for Hemarina is to have a pharma background ... is no old or new model, but there is old school thinking and open school thinking. We are clearly conscious of this within Sanofi and ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Sanofi is now in “exclusive negotiations ... With the French government saying that it has received assurances from New York City-based CD&R that it will keep Opella’s manufacturing facilities ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...

A month after making a foray into the bustling radioligand field, Sanofi is further allying itself with Orano Med, paying ...

Sept 24 (Reuters) - Sanofi (SASY.PA), opens new tab has received two separate bids ... a Sanofi spokesperson told Reuters. No decision has been made yet and we expect to select the best option ...

Sanofi (SNYNF) announced it has entered into exclusive negotiations to sell a 50 percent controlling stake in its consumer healthcare ...

French pharmaceutical company Sanofi had asked suitors to revise their proposals for the Opella business, Bloomberg News reported earlier this week. The new bids may exclude parts of the Gold Bond ...

Sanofi is deepening its commitment to targeted radiation treatments for cancer with a €300 million equity investment in a new entity pursuing next-generation radioligand therapies. The new ...